HR Execs on the Move

Young Bill Roumbospa and Fugett

www.grangerdevelopment.com

 
Young Bill Roumbospa and Fugett is a Pensacola, FL-based company in the Business Services sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Labette Health

Located in the heart of Southeast Kansas, Labette Health is a 99-bed hospital that provides acute, intensive and inpatient rehabilitation services. Labette Health is situated at the southern edge of Parsons, a community of 11,500 residents. Serving a six-county area since 1961, Labette Health has earned recognition as a respected regional medical center renowned for its comprehensive healthcare services, skilled and caring employees, state-of-the-art medical technology, and dedicated and talented medical staff. Mission We are dedicated to providing exceptional healthcare—centered around you. Vision To enhance the overall health of our communities.

High Point

High Point is a Beverly, MA-based company in the Business Services sector.

SmartWomanSecurities

Empowering a new generation of female investors through educational seminars, mentoring and meetings with successful investors and companies.

PowerFlow Communication

PowerFlow Communication is a Perris, CA-based company in the Business Services sector.

Oculis

Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.